出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年5月
ランセット市場 : タイプ 、安全ランセット (手動＆圧力作動)、標準ランセット、用途 (グルコース検査、コレステロール検査)、ガーゼ サイズ (22G 以下)、年齢層 (成人、小児科)、エンドユーザー (病院)、地域別 – 2028年までの世界予測
Lancets Market by Type (Safety Lancets (Manually & Pressure activated), Standard Lancets, Application (Glucose Testing, Cholesterol Testing), Gauze Size (22G and Below), Age Group (Adult, Pediatrics), End Users (Hospitals), Region – Global Forecast to 2028
| ページ数 | 212 |
| 図表数 | 250 |
| 種別 | 英文調査報告書 |
| 価格 |
The lancets market is projected to reach USD 3.6 Billion by 2028 from USD 2.3 Billion in 2023, at a CAGR of 9.7% during the forecast period. Growth in the lancets market is mainly driven by the growing prevalence of diabetes, the high prevalence of chronic diseases and the rising geriatric population.
However, the risk of lancet-related needlestick injuries, the reuse of lancets, and Pricing pressure owing to reimbursement cuts and budget constraints are restricting the growth of this market.
“The Safety lancet segment accounted for the highest market share in the lancets systems market, by type, during the forecast period”
Based on the type of segment, the lancets system market is categorized into standard lancets and safety lancets. Safety lancet are sub categorized into Manually Activated and Automatically activated/Pressure activated. Push Button Lancets and Side Button Lancets Manually Activated are expected to the highest growth in the market which attributed to the growing geriatric population.
“Glucose Testing application accounted for the highest CAGR during the forecast period.”
Based on type, the application market is segmented into Glucose Testing, Hemoglobin Testing, Coagulation Testing, Cholesterol Testingm, Allergy Testing, Neonatal Screening and Other Applications. In 2022, the Glucose Testing dominated the market and the lancets market to observe the highest growth rate. Factors supporting the growth of the market is due to the growing prevalence of diabetes and increasing adoption of self-monitoring devices.
“The North America segment accounted for the highest market share in the lancets systems market, by region, during the forecast period”
Based on the region, the global lancets market is categorized into North America, Europe, Asia Pacific, and Rest of the world. North America is expected to witness high market share during the forecast period. Rising prevalence of various chronic diseases which is attributed to the demand of rising number of hospitals and surgical centers are also supporting the growth of the lancets market.
Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (32%), Tier 2 (46%), and Tier 3 (22%)
• By Designation: C-level (40%), Director-level (26%), and Others (32%)
• By Region: North America (35%), Asia- Pacific (21%), Europe (30%), Latin America (14%) and Middle East & Africa(3%)
Prominent companies include Becton, Dickinson and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), B. Braun SE (Germany), Abbott Laboratories (US), Greiner Bio-One International GmbH (Austria), Ypsomed (Switzerland), Terumo Corporation (Japan), Owen Mumford (UK), HTL-STREFA S.A. (Poland), ARKRAY, Inc. (Japan), SARSTEDT AG & Co. KG (Germany), SteriLance Medical (China), Medline Industries (US), AgaMatrix Holdings LLC (US), ACON Laboratories, Inc. (US), SANLI Medical & Health Service (China), Allison Medical Inc. (US), GlucoRx Limited (UK), FL Medical s.r.l. (Italy), A. Menarini Diagnostics s.r.l (Italy), CML Biotech (India), Neomedic (Spain), MHC Medical Products (US), and Disera Tıbbi Malzeme Lojistik Sanayi ve Ticaret A.S. (Turkey).
Research Coverage
This research report categorizes the lancets market by type (Safety and Standard lancets), by application (Glucose Testing, Hemoglobin Testing, Coagulation Testing, Cholesterol Testing, Allergy Testing, Neonatal Screening and Other Applications), by end user (Hospitals, Clinics and Ambulatory Surgery Centers, Homecare settings and Other end users (Diagnostic centers, Nursing Homes, Long Term Acute Care Centers, Emergency Medical Service Providers, and Academic Research Institutes), and region (North America, Europe, Asia Pacific and Rest of world). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the lancets market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the lancets market. Competitive analysis of upcoming startups in the Lancets market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall Lancets market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (Growing prevalence of diabetes and increasing adoption of self-monitoring devices, Rising prevalence of various chronic diseases, Increasing demand for painless lancets, Growing geriatric population, Rising number of hospitals and surgical centers), restraints (Increasing incidence of lancet-related needlestick injuries and infections and Pricing pressure owing to reimbursement cuts and budget constraints) opportunities (Increasing incidence of lancet-related needlestick injuries and infections and Pricing pressure owing to reimbursement cuts and budget constraints), and challenges (Reuse of lancets) influencing the growth of the lancets market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the Lancets market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the lancets market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the Lancets market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Becton, Dickinson and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), B. Braun SE (Germany), Abbott Laboratories (US), and Greiner Bio-One International GmbH (Austria) and Terumo Corporation (Japan) among others in the lancets market strategies.
目次
1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS AND EXCLUSIONS 29
1.3 MARKET SCOPE 30
1.3.1 MARKETS COVERED 30
FIGURE 1 LANCETS MARKET SEGMENTATION 30
1.3.2 GEOGRAPHIC SCOPE 30
1.3.3 YEARS CONSIDERED 31
1.4 CURRENCY CONSIDERED 31
1.5 LIMITATIONS 31
1.6 MARKET STAKEHOLDERS 32
1.7 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 2 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 33
2.1.1.1 Secondary sources 35
2.1.2 PRIMARY DATA 35
FIGURE 3 PRIMARY SOURCES 35
2.1.2.1 Key data from primary sources 36
2.1.2.2 Key industry insights 37
2.1.2.3 Breakdown of primary interviews 37
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND- SIDE PARTICIPANTS 37
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS 38
2.2 MARKET SIZE ESTIMATION 38
FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION 39
TABLE 1 LANCETS MARKET: COUNTRY-LEVEL ANALYSIS (1/2) 40
FIGURE 7 LANCETS MARKET: COUNTRY-LEVEL ANALYSIS (2/2) 41
2.2.1 GROWTH FORECAST 41
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42
FIGURE 9 TOP-DOWN APPROACH 42
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 44
FIGURE 10 DATA TRIANGULATION METHODOLOGY 44
2.4 MARKET SHARE ANALYSIS 45
2.5 ASSUMPTIONS 45
2.6 MARKET INDICATORS AND THEIR IMPACT 46
2.7 RISK ASSESSMENT 46
TABLE 2 RISK ASSESSMENT 46
2.8 IMPACT OF RECESSION: LANCETS MARKET 47
3 EXECUTIVE SUMMARY 48
FIGURE 11 LANCETS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 48
FIGURE 12 LANCETS MARKET, BY GAUGE SIZE, 2023 VS. 2028 (USD MILLION) 49
FIGURE 13 LANCETS MARKET, BY AGE GROUP, 2023 VS. 2028 (USD MILLION) 49
FIGURE 14 LANCETS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 50
FIGURE 15 LANCETS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 50
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF LANCETS MARKET 51
4 PREMIUM INSIGHTS 52
4.1 LANCETS MARKET OVERVIEW 52
FIGURE 17 INCREASING INCIDENCE OF DIABETES TO DRIVE MARKET 52
4.2 NORTH AMERICA: LANCETS MARKET, BY TYPE AND COUNTRY (2022) 53
FIGURE 18 SAFETY LANCETS HELD LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 53
4.3 LANCETS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
FIGURE 19 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
FIGURE 20 LANCETS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55
5.2.1 DRIVERS 56
5.2.1.1 Growing prevalence of diabetes and increasing adoption of self-monitoring devices 56
FIGURE 21 INCIDENCE OF DIABETES, 2021 VS. 2045 (MILLION) 56
5.2.1.2 Rising prevalence of various chronic diseases 57
FIGURE 22 US: NUMBER OF PEOPLE WITH CHRONIC CONDITIONS, 1995–2030 (MILLION) 57
5.2.1.3 Increasing demand for painless lancets 57
5.2.1.4 Growing geriatric population 58
TABLE 3 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2030 58
5.2.1.5 Rising number of hospitals and surgical centers 59
5.2.2 RESTRAINTS 59
5.2.2.1 Increasing incidence of lancet-related needlestick injuries and infections 59
5.2.2.2 Pricing pressure owing to reimbursement cuts and budget constraints 60
5.2.3 OPPORTUNITIES 60
5.2.3.1 High growth prospects in emerging countries 60
5.2.3.2 Increasing awareness of novel technologies 61
5.2.4 CHALLENGES 61
5.2.4.1 Reuse of lancets 61
5.3 VALUE CHAIN ANALYSIS 61
FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 62
5.4 SUPPLY CHAIN ANALYSIS 62
FIGURE 24 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 63
5.5 PORTER’S FIVE FORCES ANALYSIS 63
5.5.1 THREAT OF NEW ENTRANTS 63
5.5.2 INTENSITY OF COMPETITIVE RIVALRY 63
5.5.3 BARGAINING POWER OF BUYERS 64
5.5.4 BARGAINING POWER OF SUPPLIERS 64
5.5.5 THREAT OF SUBSTITUTES 64
5.6 KEY STAKEHOLDERS AND BUYING CRITERIA 64
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS 64
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS 64
TABLE 4 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP END USERS (%) 64
5.6.2 BUYING CRITERIA 65
FIGURE 26 KEY BUYING CRITERIA FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS 65
TABLE 5 KEY BUYING CRITERIA FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS 65
5.7 REGULATORY LANDSCAPE 65
5.7.1 NORTH AMERICA 65
5.7.1.1 US 65
5.7.1.2 Canada 65
TABLE 6 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 66
5.7.2 EUROPE 66
5.7.3 ASIA PACIFIC 67
5.7.3.1 Japan 67
TABLE 7 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 67
5.7.3.2 China 67
TABLE 8 CHINA: CLASSIFICATION OF MEDICAL DEVICES 68
5.7.3.3 India 69
5.8 TRADE ANALYSIS 69
TABLE 9 IMPORT DATA FOR HS CODE 901839, BY COUNTRY, 2018–2022 (USD MILLION) 69
TABLE 10 EXPORT DATA FOR HS CODE 901839, BY COUNTRY, 2018–2022 (USD MILLION) 70
5.9 ECOSYSTEM ANALYSIS 70
TABLE 11 ROLE IN ECOSYSTEM 71
FIGURE 27 KEY PLAYERS OPERATING IN LANCETS MARKET 72
5.10 PATENT ANALYSIS 73
5.11 KEY CONFERENCES AND EVENTS IN 2023–2024 74
TABLE 12 LIST OF CONFERENCES AND EVENTS 74
5.12 PRICING ANALYSIS 75
5.12.1 AVERAGE SELLING PRICE OF KEY PRODUCTS 75
TABLE 13 PRICE RANGE OF KEY PRODUCTS IN THE LANCETS MARKET (USD) 75
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 76
5.14 TECHNOLOGY ANALYSIS 76
6 LANCETS MARKET, BY TYPE 77
6.1 INTRODUCTION 78
FIGURE 28 LANCETS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 78
TABLE 14 LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 78
6.2 SAFETY LANCETS 79
TABLE 15 SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 79
TABLE 16 SAFETY LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 79
6.2.1 MANUALLY ACTIVATED LANCETS 80
TABLE 17 MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 80
TABLE 18 MANUALLY ACTIVATED LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 80
6.2.1.1 Side-button lancets 80
6.2.1.1.1 Anti-reuse measures to increase popularity among end users 80
TABLE 19 SIDE-BUTTON LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 81
6.2.1.2 Push-button lancets 81
6.2.1.2.1 Ease of use and simplicity to drive demand 81
TABLE 20 PUSH-BUTTON LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 81
6.2.2 AUTOMATICALLY ACTIVATED/PRESSURE-ACTIVATED LANCETS 82
6.2.2.1 Available in number of gauge sizes and penetration depths 82
TABLE 21 AUTOMATICALLY ACTIVATED/PRESSURE-ACTIVATED LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 82
6.3 STANDARD LANCETS 82
6.3.1 INCREASING PREVALENCE OF DIABETES TO DRIVE ADOPTION 82
TABLE 22 STANDARD LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 83
7 LANCETS MARKET, BY GAUGE SIZE 84
7.1 INTRODUCTION 85
FIGURE 29 LANCETS MARKET, BY GAUGE SIZE, 2023 VS. 2028 (USD MILLION) 85
TABLE 23 LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 86
7.2 22G AND BELOW 86
7.2.1 BENEFICIAL FOR MEDICAL TESTS THAT REQUIRE LARGER SAMPLE SIZE 86
TABLE 24 22G AND BELOW LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 86
7.3 23G–33G 87
7.3.1 WIDE AVAILABILITY OF 23G–33G LANCETS TO AID MARKET GROWTH 87
TABLE 25 23G–33G LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 87
7.4 ABOVE 33G 87
7.4.1 LESS PAIN AND DISCOMFORT TO DRIVE ADOPTION 87
TABLE 26 ABOVE 33G LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 88
8 LANCETS MARKET, BY AGE GROUP 89
8.1 INTRODUCTION 90
FIGURE 30 LANCETS MARKET, BY AGE GROUP, 2023 VS. 2028 (USD MILLION) 90
TABLE 27 LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 90
8.2 ADULT 90
8.2.1 LARGEST AND FASTEST-GROWING SEGMENT 90
TABLE 28 ADULT LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 91
8.3 PEDIATRIC 91
8.3.1 INCREASING PREVALENCE OF TYPE 1 DIABETES IN PEDIATRIC PATIENTS TO DRIVE MARKET 91
TABLE 29 PEDIATRIC LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 91
9 LANCETS MARKET, BY APPLICATION 92
9.1 INTRODUCTION 93
FIGURE 31 LANCETS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 93
TABLE 30 LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 93
9.2 GLUCOSE TESTING 94
9.2.1 RISING PREVALENCE OF DIABETES TO DRIVE MARKET 94
TABLE 31 LANCETS MARKET FOR GLUCOSE TESTING, BY REGION, 2021–2028 (USD MILLION) 94
9.3 HEMOGLOBIN TESTING 95
9.3.1 HIGH PREVALENCE OF ANEMIA TO DRIVE DEMAND 95
TABLE 32 LANCETS MARKET FOR HEMOGLOBIN TESTING, BY REGION, 2021–2028 (USD MILLION) 95
9.4 COAGULATION TESTING 95
9.4.1 RISING PREVALENCE OF LIVER DISEASES, THROMBOPHILIA, AND HEMOPHILIA TO DRIVE MARKET 95
TABLE 33 LANCETS MARKET FOR COAGULATION TESTING, BY REGION, 2021–2028 (USD MILLION) 96
9.5 CHOLESTEROL TESTING 96
9.5.1 RISING DEMAND FOR CHOLESTEROL HOME TEST KITS TO SUPPORT MARKET GROWTH 96
TABLE 34 LANCETS MARKET FOR CHOLESTEROL TESTING, BY REGION, 2021–2028 (USD MILLION) 97
9.6 ALLERGY TESTING 97
9.6.1 HIGH DEMAND FOR SPT TO PROPEL MARKET 97
TABLE 35 LANCETS MARKET FOR ALLERGY TESTING, BY REGION, 2021–2028 (USD MILLION) 98
9.7 NEONATAL SCREENING 98
9.7.1 GROWING NEED FOR DRY BLOOD SPOT TESTS TO DRIVE MARKET 98
TABLE 36 LANCETS MARKET FOR NEONATAL SCREENING, BY REGION, 2021–2028 (USD MILLION) 99
9.8 OTHER APPLICATIONS 99
TABLE 37 LANCETS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 100
10 LANCETS MARKET, BY END USER 101
10.1 INTRODUCTION 102
FIGURE 32 LANCETS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 102
TABLE 38 LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 102
10.2 HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS 103
10.2.1 INCREASING INCIDENCE OF CHRONIC DISEASES TO DRIVE ADOPTION OF LANCETS 103
TABLE 39 LANCETS MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY REGION, 2021–2028 (USD MILLION) 104
10.3 HOME CARE SETTINGS 104
10.3.1 TECHNOLOGICAL ADVANCEMENTS IN SELF/HOME CARE GLUCOSE MONITORING SYSTEMS TO DRIVE MARKET 104
TABLE 40 LANCETS MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION) 104
10.4 OTHER END USERS 105
TABLE 41 LANCETS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 105
11 LANCETS MARKET, BY REGION 106
11.1 INTRODUCTION 107
TABLE 42 LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 107
11.2 NORTH AMERICA 107
11.2.1 NORTH AMERICA: IMPACT OF RECESSION 107
FIGURE 33 NORTH AMERICA: LANCETS MARKET SNAPSHOT 108
TABLE 43 NORTH AMERICA: LANCETS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 44 NORTH AMERICA: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 109
TABLE 45 NORTH AMERICA: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 109
TABLE 46 NORTH AMERICA: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 109
TABLE 47 NORTH AMERICA: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 109
TABLE 48 NORTH AMERICA: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 110
TABLE 49 NORTH AMERICA: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
TABLE 50 NORTH AMERICA: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 110
11.2.2 US 111
11.2.2.1 Increasing incidence and prevalence of lifestyle diseases to drive market 111
TABLE 51 US: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 111
TABLE 52 US: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 111
TABLE 53 US: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 112
TABLE 54 US: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 112
TABLE 55 US: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 112
TABLE 56 US: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 113
TABLE 57 US: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 113
11.2.3 CANADA 113
11.2.3.1 Rising incidence of allergies to drive market 113
TABLE 58 CANADA: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 59 CANADA: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 60 CANADA: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 61 CANADA: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 115
TABLE 62 CANADA: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 115
TABLE 63 CANADA: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 115
TABLE 64 CANADA: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 116
11.3 EUROPE 116
11.3.1 EUROPE: IMPACT OF RECESSION 116
TABLE 65 EUROPE: LANCETS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 66 EUROPE: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 67 EUROPE: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 68 EUROPE: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 69 EUROPE: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 118
TABLE 70 EUROPE: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 118
TABLE 71 EUROPE: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 119
TABLE 72 EUROPE: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 119
11.3.2 GERMANY 119
11.3.2.1 Germany to dominate European lancets market 119
TABLE 73 GERMANY: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 74 GERMANY: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 75 GERMANY: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 76 GERMANY: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 121
TABLE 77 GERMANY: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 121
TABLE 78 GERMANY: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 121
TABLE 79 GERMANY: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 122
11.3.3 FRANCE 122
11.3.3.1 Growing public-private collaborations for product development to support market growth 122
TABLE 80 FRANCE: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 81 FRANCE: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 82 FRANCE: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 83 FRANCE: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 123
TABLE 84 FRANCE: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 123
TABLE 85 FRANCE: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124
TABLE 86 FRANCE: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 124
11.3.4 UK 124
11.3.4.1 Increasing prevalence of lifestyle diseases to drive market 124
TABLE 87 UK: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 88 UK: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 89 UK: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 90 UK LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 126
TABLE 91 UK: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 126
TABLE 92 UK: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126
TABLE 93 UK: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 127
11.3.5 ITALY 127
11.3.5.1 Slower growth in healthcare sector to restrain market growth 127
TABLE 94 ITALY: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 95 ITALY: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 96 ITALY: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 97 ITALY: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 128
TABLE 98 ITALY: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 128
TABLE 99 ITALY: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 129
TABLE 100 ITALY: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 129
11.3.6 SPAIN 129
11.3.6.1 Increasing funding for research to boost market growth 129
TABLE 101 SPAIN: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 102 SPAIN: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 103 SPAIN: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 104 SPAIN: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 131
TABLE 105 SPAIN: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 131
TABLE 106 SPAIN: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 131
TABLE 107 SPAIN: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 132
11.3.7 REST OF EUROPE 132
TABLE 108 REST OF EUROPE: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 109 REST OF EUROPE: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 110 REST OF EUROPE: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 111 REST OF EUROPE: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 133
TABLE 112 REST OF EUROPE: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 133
TABLE 113 REST OF EUROPE: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 134
TABLE 114 REST OF EUROPE: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 134
11.4 ASIA PACIFIC 134
11.4.1 ASIA PACIFIC: IMPACT OF RECESSION 135
FIGURE 34 ASIA PACIFIC: LANCETS MARKET SNAPSHOT 136
TABLE 115 ASIA PACIFIC: LANCETS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 116 ASIA PACIFIC: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 117 ASIA PACIFIC: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 118 ASIA PACIFIC: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 119 ASIA PACIFIC: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 138
TABLE 120 ASIA PACIFIC: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 138
TABLE 121 ASIA PACIFIC: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 139
TABLE 122 ASIA PACIFIC: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 139
11.4.2 JAPAN 139
11.4.2.1 Well-established healthcare system to support market growth 139
TABLE 123 JAPAN: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 124 JAPAN: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 125 JAPAN: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 126 JAPAN: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 141
TABLE 127 JAPAN: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 141
TABLE 128 JAPAN: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 141
TABLE 129 JAPAN: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 142
11.4.3 CHINA 142
11.4.3.1 Fastest-growing market for lancets 142
TABLE 130 CHINA: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 131 CHINA: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 132 CHINA: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 133 CHINA: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 143
TABLE 134 CHINA: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 144
TABLE 135 CHINA: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144
TABLE 136 CHINA: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 144
11.4.4 INDIA 145
11.4.4.1 High burden of chronic diseases to support market growth 145
TABLE 137 INDIA: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 138 INDIA: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 139 INDIA: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 140 INDIA: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 146
TABLE 141 INDIA: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 146
TABLE 142 INDIA: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 147
TABLE 143 INDIA: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 147
11.4.5 SOUTH KOREA 147
11.4.5.1 Increasing government initiatives to aid market growth 147
TABLE 144 SOUTH KOREA: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 145 SOUTH KOREA: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 146 SOUTH KOREA: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 147 SOUTH KOREA: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 148
TABLE 148 SOUTH KOREA: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 149
TABLE 149 SOUTH KOREA: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 149
TABLE 150 SOUTH KOREA: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 149
11.4.6 REST OF ASIA PACIFIC 150
TABLE 151 REST OF ASIA PACIFIC: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 152 REST OF ASIA PACIFIC: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 153 REST OF ASIA PACIFIC: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 154 REST OF ASIA PACIFIC: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 151
TABLE 155 REST OF ASIA PACIFIC: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 151
TABLE 156 REST OF ASIA PACIFIC: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 151
TABLE 157 REST OF ASIA PACIFIC: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 152
11.5 REST OF THE WORLD 152
TABLE 158 REST OF THE WORLD: LANCETS MARKET, BY REGION, 2021–2028 (USD MILLION) 152
TABLE 159 REST OF THE WORLD: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 160 REST OF THE WORLD: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 161 REST OF THE WORLD: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 162 REST OF THE WORLD: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 153
TABLE 163 REST OF THE WORLD: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 153
TABLE 164 REST OF THE WORLD: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 154
TABLE 165 REST OF THE WORLD: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 154
11.5.1 LATIN AMERICA 154
11.5.1.1 Rising prevalence of diabetes and cancer to support market growth 154
11.5.1.2 Latin America: Impact of recession 155
TABLE 166 LATIN AMERICA: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 167 LATIN AMERICA: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 168 LATIN AMERICA: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 169 LATIN AMERICA: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 156
TABLE 170 LATIN AMERICA: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 156
TABLE 171 LATIN AMERICA: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157
TABLE 172 LATIN AMERICA: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 157
11.5.2 MIDDLE EAST AND AFRICA 157
11.5.2.1 Rising geriatric population and increasing prevalence of chronic diseases to drive market 157
11.5.2.2 Middle East & Africa: Impact of recession 158
TABLE 173 MIDDLE EAST AND AFRICA: LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 174 MIDDLE EAST AND AFRICA: SAFETY LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 175 MIDDLE EAST AND AFRICA: MANUALLY ACTIVATED LANCETS MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 176 MIDDLE EAST AND AFRICA: LANCETS MARKET, BY GAUGE SIZE, 2021–2028 (USD MILLION) 160
TABLE 177 MIDDLE EAST AND AFRICA: LANCETS MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 160
TABLE 178 MIDDLE EAST AND AFRICA: LANCETS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 160
TABLE 179 MIDDLE EAST AND AFRICA: LANCETS MARKET, BY END USER, 2021–2028 (USD MILLION) 161
12 COMPETITIVE LANDSCAPE 162
12.1 OVERVIEW 162
TABLE 180 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN LANCETS MARKET 162
12.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 163
FIGURE 35 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN LANCETS MARKET 163
12.3 MARKET SHARE ANALYSIS 164
TABLE 181 LANCETS MARKET: DEGREE OF COMPETITION 164
12.4 COMPETITIVE LEADERSHIP MAPPING 164
12.4.1 STARS 165
12.4.2 EMERGING LEADERS 165
12.4.3 PERVASIVE PLAYERS 165
12.4.4 PARTICIPANTS 165
FIGURE 36 LANCETS MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022 166
12.5 COMPANY EVALUATION QUADRANT FOR SMES/STARTUPS 167
12.5.1 PROGRESSIVE COMPANIES 167
12.5.2 STARTING BLOCKS 167
12.5.3 RESPONSIVE COMPANIES 167
12.5.4 DYNAMIC COMPANIES 167
FIGURE 37 LANCETS MARKET: COMPANY EVALUATION MATRIX FOR SMES/STARTUPS, 2022 168
12.6 COMPETITIVE BENCHMARKING 169
TABLE 182 LANCETS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 169
12.7 COMPANY FOOTPRINT ANALYSIS 170
TABLE 183 FOOTPRINT ANALYSIS OF COMPANIES 170
TABLE 184 REGIONAL FOOTPRINT ANALYSIS OF COMPANIES 171
TABLE 185 PRODUCT FOOTPRINT ANALYSIS OF COMPANIES 172
12.8 COMPETITIVE SCENARIO 173
12.8.1 PRODUCT LAUNCHES 173
TABLE 186 KEY PRODUCT LAUNCHES, JANUARY 2020–MAY 2023 173
12.8.2 DEALS 173
TABLE 187 KEY DEALS, JANUARY 2020–MAY 2023 173
12.8.3 OTHER DEVELOPMENTS 174
TABLE 188 OTHER KEY DEVELOPMENTS, JANUARY 2020–MAY 2023 174
13 COMPANY PROFILES 175
13.1 KEY PLAYERS 175
(Business overview, Products offered, Recent Developments, MNM view)*
13.1.1 BECTON, DICKINSON AND COMPANY 175
TABLE 189 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 175
FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 176
13.1.2 F. HOFFMANN-LA ROCHE LTD. 178
TABLE 190 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 178
FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 179
13.1.3 YPSOMED 182
TABLE 191 YPSOMED: BUSINESS OVERVIEW 182
FIGURE 40 YPSOMED: COMPANY SNAPSHOT (2022) 183
13.1.4 B. BRAUN SE 185
TABLE 192 B. BRAUN SE: BUSINESS OVERVIEW 185
FIGURE 41 B. BRAUN SE: COMPANY SNAPSHOT (2022) 186
13.1.5 TERUMO CORPORATION 188
TABLE 193 TERUMO CORPORATION: BUSINESS OVERVIEW 188
FIGURE 42 TERUMO CORPORATION: COMPANY SNAPSHOT (2022) 189
13.1.6 GREINER BIO-ONE INTERNATIONAL GMBH 191
TABLE 194 GREINER BIO-ONE INTERNATIONAL GMBH: BUSINESS OVERVIEW 191
FIGURE 43 GREINER BIO-ONE INTERNATIONAL GMBH: COMPANY SNAPSHOT (2021) 192
13.1.7 ABBOTT LABORATORIES 194
TABLE 195 ABBOTT LABORATORIES: BUSINESS OVERVIEW 194
FIGURE 44 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 195
13.1.8 OWEN MUMFORD 196
TABLE 196 OWEN MUMFORD: BUSINESS OVERVIEW 196
13.1.9 HTL-STREFA S.A. 198
TABLE 197 HTL-STREFA S.A.: BUSINESS OVERVIEW 198
13.1.10 ARKRAY, INC. 199
TABLE 198 ARKRAY, INC.: BUSINESS OVERVIEW 199
13.1.11 SARSTEDT AG & CO. KG 200
TABLE 199 SARSTEDT AG & CO. KG: BUSINESS OVERVIEW 200
13.1.12 STERILANCE MEDICAL (SUZHOU) INC. 201
TABLE 200 STERILANCE MEDICAL (SUZHOU): BUSINESS OVERVIEW 201
13.1.13 MEDLINE INDUSTRIES 203
TABLE 201 MEDLINE INDUSTRIES: BUSINESS OVERVIEW 203
13.1.14 AGAMATRIX, INC. 204
TABLE 202 AGAMATRIX, INC.: BUSINESS OVERVIEW 204
13.1.15 ACON LABORATORIES, INC. 205
TABLE 203 ACON LABORATORIES, INC.: BUSINESS OVERVIEW 205
13.1.16 SANLI MEDICAL & HEALTH SERVICE 206
TABLE 204 SANLI MEDICAL & HEALTH SERVICE: BUSINESS OVERVIEW 206
13.1.17 ALLISON MEDICAL, INC. 207
TABLE 205 ALLISON MEDICAL, INC.: BUSINESS OVERVIEW 207
13.1.18 GLUCORX LIMITED 208
TABLE 206 GLUCORX LIMITED: BUSINESS OVERVIEW 208
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 209
13.2.1 FL MEDICAL S.R.L 209
13.2.2 MHC MEDICAL PRODUCTS, LLC 209
13.2.3 NEOMEDIC 210
13.2.4 CML BIOTECH LTD. 210
13.2.5 DISERA TIBBI MALZEME LOJISTIK SANAYI VE TICARET A.Ş. 211
13.2.6 A. MENARINI DIAGNOSTICS S.R.L 211
14 APPENDIX 212
14.1 DISCUSSION GUIDE 212
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 216
14.3 CUSTOMIZATION OPTIONS 218
14.4 RELATED REPORTS 218
14.5 AUTHOR DETAILS 219